Clinical Cancer Research, Vol 2, Issue 8 1285-1288, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

AP Kudelka, R Winn, CL Edwards, G Downey, H Greenberg, SR Dakhil, RS Freedman, E Loyer, J Rusinkiewicz, P Gacrama, R Fueger and JJ Kavanagh
Section of Gynecologic/Medical Oncology, Department of Community Oncology, University of Texas, Houston, Texas 77030-4095, USA.

Twenty-six patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel, 250 mg/m2 over 3 h every 21 days. They received steroid, H1 and H2 blocker premedications, and granulocyte-colony-stimulating factor (G-CSF) support (5 microgram/kg/day). No prior chemotherapy, except as a radiation sensitizer, was allowed. The median age was 50 (range, 36-81) years, and performance status Zubrod was 1 (range, 0-2). Eight (33%) patients had prior surgery, and 22 (92%) had prior radiation therapy. Twenty-four patients were evaluable for response; 2 were later found to be ineligible. Five patients had partial responses (21%; 95% confidence interval, 6-40%), and 14 (58%; 95% confidence interval, 35-78%) had stable disease. The median duration of response was 10 (range, 3-27+) weeks. The responses were within the radiation port (four responses) and outside of it (one response). The median interval from the start of irradiation to the start of paclitaxel in responding patients was 94 weeks, whereas in patients with stable disease it was 68 weeks, and in patients whose disease progressed it was 46 weeks. Eighty-eight percent of the 105 cycles of paclitaxel were administered at a dose of 250 mg/m2 or higher. Granulocytopenia was brief and noncumulative, with grades 3 and 4 experienced by 5 and 3 patients, respectively. G-CSF was used for a median of 7 (range, 2-14) days/cycle. Anemia was mild, with G3 noted in 3 patients, and thrombocytopenia was not significant. Infections and musculoskeletal pain were mild and infrequent. Sensory (14 patients G1 or G2 and 2 patients G3) and motor (4 patients G1 or G2 and 1 patient G3) neurotoxicity was noted. There was no significant cardiovascular toxicity. Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support.

This article has been cited by other articles:

				A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, L. Cetina, L. Rivera, I. Mariscal, G. Montalvo, E. Gomez, J. de la Garza, G. Chanona, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation Ann. Onc., August 1, 2003; 14(8): 1278 - 1284. [Abstract] [Full Text] [PDF]

				J. V. Fiorica Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan Oncologist, October 1, 2002; 7(90005): 36 - 45. [Abstract] [Full Text] [PDF]

				J. P. Curtin, J. A. Blessing, K. D. Webster, P. G. Rose, A. R. Mayer, W. C. Fowler Jr, J. H. Malfetano, and R. D. Alvarez Paclitaxel, an Active Agent in Nonsquamous Carcinomas of the Uterine Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., March 1, 2001; 19(5): 1275 - 1278. [Abstract] [Full Text] [PDF]